Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests ocrelizumab in minority MS patients

NCT ID NCT04377555

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well ocrelizumab works in Black and Hispanic patients with relapsing multiple sclerosis (MS). About 179 participants received the drug and were monitored for relapses, disability progression, and brain lesions over 48 weeks. The goal was to see if the treatment controls disease activity and reduces nerve damage in these groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

179 people

The number who actually took part.

Started

Jul 2020

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of RMS with Expanded Disability Status Scale (EDSS) 0-5.5 at enrollment * Participants who self-identify as Black or African American or Hispanic/Latino American * Treatment-naïve or initiating first or second switch from receiving treatment with certain disease modifying therapies (DMTs) including interferon or glatiramer acetate or dimethyl fumarate (DMF); or siponimod; or fingolimod; or diroximel fumarate; or teriflunomide; or ozanimod; or natalizumab * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for 6 months after the final dose of ocrelizumab * Neurologically stable for at least 30 days prior to randomization and baseline assessments Exclusion Criteria: * Diagnosis of secondary progressive MS without relapses for at least 1 year (nonactive or inactive SPMS) * Primary Progressive Multiple Sclerosis (PPMS) * Participants with contraindication to gadolinium based contrast agent for MRI and participants who cannot tolerate MRI procedure * Infection Related * Cancer Related * Pregnant or lactating, or intending to become pregnant during the study * Other Medical Conditions * Known presence or history of other neurologic disorders * Vaccinations: Receipt of a live vaccine, or attenuated, or inactivated / component vaccine within 6 weeks prior to first administration of ocrelizumab * Laboratory: abnormalities or findings at screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis, relapsing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis Recurrence relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis, relapsing

Contacts and locations

Locations

  • Atlanta Neuroscience Institute

    Atlanta, Georgia, 30327, United States

  • Baptist Neurology - Beaches

    Jacksonville Beach, Florida, 32250, United States

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013, United States

  • Baylor College of Medicine Medical Center

    Houston, Texas, 77030, United States

  • Centro Internacional De Mercadeo

    Guaynabo, 969, Puerto Rico

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20007, United States

  • Guilford Neurologic Research Partners, LLC

    Greensboro, North Carolina, 27401, United States

  • Hackensack University Medical Center

    Paramus, New Jersey, 07652, United States

  • Jefferson University Hospitals, Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • Johns Hopkins University Neurology Research Office

    Baltimore, Maryland, 21287, United States

  • Josephson Wallack Munshower Neurology PC

    Indianapolis, Indiana, 46256, United States

  • Keck School of Medicine of USC

    Los Angeles, California, 90033-5315, United States

  • Multiple Sclerosis Center of Tidewater

    Norfolk, Virginia, 23502, United States

  • Neurology Clinic - Cordova

    Cordova, Tennessee, 38018, United States

  • North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic

    Frisco, Texas, 75034, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612-3244, United States

  • SUNY Upstate Medical Center

    Syracuse, New York, 13210, United States

  • Shepherd Center Inc.

    Atlanta, Georgia, 30309, United States

  • The Aga Khan University-Kenya.

    Nairobi, 00100, Kenya

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Maryland Medical Center

    Baltimore, Maryland, 21201-1642, United States

  • University of Miami Miller School of Medicine

    Miami, Florida, 33136, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37204, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Wayne State University

    Detroit, Michigan, 48201, United States

  • Wheaton Franciscan Healthcare - St. Francis Outpatient Center

    Milwaukee, Wisconsin, 53215, United States